Monopar climbs on 'promising' preclinical data from cancer treatment trial

Monopar Therapeutics

22/02/2024 12:26

** Shares of Monopar Therapeutics  MNPR.O  rise ~43% to 81
cents premarket
    ** Co says preclinical data evaluating its therapy MNPR-101
showed "compelling and durable" anti-tumor benefits
    ** Says an injection of the radiopharmaceutical agent showed
near complete elimination of the tumor when tested for breast
cancer and pancreatic cancer in mouse models
    ** Adds that MNPR has received clearance in Australia to
start human trials with advanced cancer patients
    ** Up to last close, stock down 83% in the last 12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))